Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22047601 | 0.72 | HPGD (0.36) | HRH4HRH3ALDH1A1MEN1GLA | |
| SCHEMBL2068070 | 0.72 | CCR1 (0.40) | HRH4HRH3ALDH1A1MEN1KMT2A | |
| SCHEMBL3147727 | 0.69 | DAO (0.44) | MEN1KMT2A | |
| SCHEMBL13201391 | 0.69 | MEN1 (0.36) | ALDH1A1MEN1KMT2A | |
| SCHEMBL19413644 | 0.69 | GABRA1 (0.34) | ALDH1A1MEN1KMT2AP2RX3P2RX2 | |
| SCHEMBL30480258 | 0.66 | BTK (0.37) | MEN1KMT2ALMNA | |
| SCHEMBL23733959 | 0.64 | GABRA1 (0.44) | ALDH1A1 | |
| SCHEMBL13636700 | 0.64 | GABRP (0.42) | ALDH1A1MEN1KMT2A | |
| SCHEMBL18888882 | 0.64 | HTT (0.33) | ALDH1A1GLA | |
| SCHEMBL12270784 | 0.63 | MAP3K7 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711013-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2020-07-14 | — | — | US | disclosed |
| US-20190100536-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711013-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | HRH4 2291/4885HRH3 3401/4885ALDH1A1 570/4885 |
| US-20190100536-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | HRH4 2291/4885HRH3 3401/4885ALDH1A1 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.